Lin BioScience, Inc.
TWO: 6696.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhengqi Wang
- Headquarters
- Taipei, Taiwan
- IPO year
- 2018
- Market cap
- NT$32.6B
- Website
- https://www.linbioscience.com
Loading 6696…
Loading profile data…Frequently asked questions about 6696
What does Lin BioScience, Inc. (6696.TWO) do?
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD...
Where does 6696.TWO trade?
Lin BioScience, Inc. (6696.TWO) trades on the Taipei Exchange.
What sector is 6696.TWO in?
Lin BioScience, Inc. (6696.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lin BioScience, Inc.?
Zhengqi Wang is the chief executive officer of Lin BioScience, Inc. (6696.TWO).
Where is Lin BioScience, Inc. headquartered?
Lin BioScience, Inc. is headquartered in Taiwan.
Does 6696.TWO pay a dividend?
Lin BioScience, Inc. (6696.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6696.TWO go public?
Lin BioScience, Inc. (6696.TWO) completed its initial public offering in 2018.